Tadalafil 5 mg once daily resulted in a significantly greater proportion of patients achieving a 3-point IPSS improvement ( 71.1 % and 56.0 % for tadalafil and placebo patients , respectively [ OR 1.9 , 95 % CI 1.5 , 2.4 ; P < 0.001 ] ) and achieving a 25 % improvement in total IPSS randomisation to endpoint ( 61.7 % and 45.5 % for tadalafil and placebo patients , respectively [ OR 2.0 , 95 % CI 1.6 , 2.5 ; P < 0.001 ] ) .